Steroid-toxicity Insights Roundup
The Steritas team is excited by the conversations held at ACR Convergence 2023 last month, and the distinct shift in intent towards directly tackling steroid-toxicity.
Ever since the introduction of the Steritas GTI in 2017, there has been a remarkable surge in the number of clinicians and clinical researchers using Steritas's growing suite of steroid-toxicity assessment tools.
As we near the close of 2023, it feels that we are at a key inflection point in the fight against steroid-toxicity.
Jane McDowell, MBBS BSc PhD is a respiratory doctor and currently serves as an academic clinical lecturer at Queen's University Belfast in Northern Ireland. Her research interests focus on severe asthma - both the mechanisms that cause residual exacerbations in those treated with biologics as well as the measurement of steroid-toxicity among those exposed to oral glucocorticoids.
Results from a Phase 3 clinical trial reported in The New England Journal of Medicine, have highlighted the significant unmet need for effective long-term treatments for those battling polymyalgia rheumatica.
Since the publication of the GTI in 2017, there has been a remarkable surge in the number of clinicians and clinical researchers using Steritas's growing suite of steroid-toxicity assessment instruments.
Steritas is working toward a world free of steroid dependency, enabling the measurement and monitoring of steroid-toxicity to optimize treatment of inflammatory diseases and improve the quality of patient care around the world.
Learn more at steritas.com.
Sincerely,
Martha Stone
CEO, Steritas